Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$527 Mln
P/E Ratio
--
P/B Ratio
3.03
Industry P/E
--
Debt to Equity
0.16
ROE
-0.62 %
ROCE
-52.53 %
Div. Yield
0 %
Book Value
0.87
EPS
-0.48
CFO
$-344.13 Mln
EBITDA
$-344.91 Mln
Net Profit
$-465.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Savara (SVRA)
| 5.37 | 14.72 | 12.33 | -31.02 | 38.04 | 7.34 | -20.95 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Savara (SVRA)
| -34.45 | 203.23 | 25.00 | 7.83 | -74.33 | -40.82 | -48.80 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.41 | 9,808.03 | 20.22 | 23.13 | |
| 299.04 | 8,956.09 | 22.08 | 58.42 | |
| 26.78 | 9,559.25 | -- | -28.77 | |
| 104.84 | 10,030.35 | 30.81 | 14.16 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage... for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania. Address: 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047 Read more
Chairman & CEO
Mr. Matthew Pauls J.D., M.B.A.
Chairman & CEO
Mr. Matthew Pauls J.D., M.B.A.
Headquarters
Langhorne, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Savara Inc (SVRA) stood at $ 213 Mln as on 31-Dec-24
The share price of Savara Inc (SVRA) is $3.24 (NASDAQ) as of 24-Apr-2025 11:43 EDT. Savara Inc (SVRA) has given a return of 38.04% in the last 3 years.
Savara Inc (SVRA) has a market capitalisation of $ 527 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Savara Inc (SVRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Savara Inc (SVRA) and enter the required number of quantities and click on buy to purchase the shares of Savara Inc (SVRA).
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania. Address: 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047
The CEO & director of Mr. Matthew Pauls J.D., M.B.A.. is Savara Inc (SVRA), and CFO & Sr. VP is Mr. Matthew Pauls J.D., M.B.A..
There is no promoter pledging in Savara Inc (SVRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Savara Inc. (SVRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-61.5
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Savara Inc (SVRA) was $0 Mln.
$-0.02
(
